Source comparison
BPC-157 for IBS: Clinical vs Anecdotal Use
Mechanism Studied Mucosal repair, cytokine reduction, barrier stabilisation via VEGF/FGF upregulation Self-reported symptom relief, no controlled measurement of permeability or inflammation Animal data is robust but not validated in humans. Mechanism plausibil
This comparison does not assign a generated winner or score.
- Mechanism Studied
- Mucosal repair, cytokine reduction, barrier stabilisation via VEGF/FGF upregulation
- Self-reported symptom relief, no controlled measurement of permeability or inflammation
- Animal data is robust but not validated in humans. Mechanism plausibility is high for IBS-D with barrier dysfunction
- Evidence Quality
- 40+ peer-reviewed rodent studies showing accelerated healing in colitis, fistula, NSAID injury models
- Zero human RCTs for IBS; anecdotal reports from online peptide communities and anti-aging clinics
- Preclinical evidence is compelling; clinical evidence is non-existent
- Typical Dosage (Rodent Equivalent)
- 10 micrograms/kg body weight subcutaneously in rats, equivalent to ~700 micrograms for a 70kg human (not validated)
- Users report 250–500 micrograms subcutaneously daily, with no dose-finding studies to guide safety or efficacy
- Dosing is speculative. Animal-to-human conversion formulas exist but haven't been tested in trials
- Side Effects Documented
- None reported in animal toxicity studies at 10x therapeutic dose; no adverse histology in liver, kidney, or CNS tissue
- Anecdotal reports of injection site irritation, rare GI upset if oral form used
- No formal human safety data. Peptide appears well-tolerated in animals but clinical side effect profile unknown
- FDA Status
- Not approved for any indication; classified as a research chemical
- Not approved; available from compounding research suppliers under peptide research exemptions
- Legal grey area. Purchasable but not medically prescribed